Recommendations for essential medicines for multiple sclerosis in low-resource settings
- 31 December 2024
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (4) , 464-473
Abstract
Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that, when untreated, can lead to significant disability in young adults. Despite the increase in the number of disease-modifying therapies (DMTs), many people living with MS in low-resource settings do not have access to treatment. Objective: The primary aim was to develop recommendations on the minimum essential DMTs for MS that should be available in low-resource settings. Methods: The Multiple Sclerosis International Federation established an independent, international panel including healthcare professionals and people with MS. This panel, in collaboration with the Cochrane MS Group and McMaster GRADE Centre, reviewed evidence for use of MS DMTs following standardized GRADE protocols including consideration of balance of benefits and harms; certainty of evidence; resources required and cost-effectiveness and values, equity, feasibility and availability in low-resource settings. Results: For active and/or worsening forms of relapsing MS, the panel recommends use of ocrelizumab, cladribine, fingolimod, dimethyl fumarate, interferon beta and glatiramer acetate. For active and/or worsening forms of progressive MS, the panel recommends use of rituximab, ocrelizumab, glatiramer acetate, fingolimod and interferon beta. Conclusions: Recommendations for the minimum essential DMTs for MS in low-resource settings were developed based on robust consideration of evidence and relevant context.Keywords
This publication has 10 references indexed in Scilit:
- Chronic Disease in Low-Resource Settings: Prevention and Management Throughout the Continuum of Care—A Call for PapersInternational Journal of Environmental Research and Public Health, 2023
- Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosisMultiple Sclerosis Journal – Experimental, Translational and Clinical, 2021
- Ethical use of off-label disease-modifying therapies for multiple sclerosisMultiple Sclerosis Journal, 2021
- Supporting effective participation in health guideline development groups: The Guideline Participant ToolJournal of Clinical Epidemiology, 2021
- Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Neurology, 2019
- GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelinesBMJ, 2016
- Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequityNeurology, 2014
- Defining the clinical course of multiple sclerosisNeurology, 2014
- Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterpriseCanadian Medical Association Journal, 2013
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011